• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    GCC Car T Cell Therapy Market

    ID: MRFR/Pharma/48112-HCR
    200 Pages
    Garvit Vyas
    September 2025

    GCC CAR T Cell Therapy Market Research Report By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases), By Cell Source (Autologous, Allogeneic, Gene-Edited), By Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma), andBy End-user (Hospitals, Research Institutes, Cancer Treatment Centers)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    GCC Car T Cell Therapy Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    GCC Car T Cell Therapy Market Summary

    The GCC CAR T Cell Therapy market is poised for substantial growth, expanding from 300 USD Million in 2024 to 1500 USD Million by 2035.

    Key Market Trends & Highlights

    GCC CAR T Cell Therapy Key Trends and Highlights

    • The market is projected to grow at a compound annual growth rate of 15.76 percent from 2025 to 2035.
    • By 2035, the market valuation is expected to reach 1500 USD Million, indicating a robust expansion trajectory.
    • In 2024, the market is valued at 300 USD Million, reflecting the current investment in CAR T Cell Therapy in the GCC region.
    • Growing adoption of CAR T Cell Therapy due to increasing prevalence of hematological malignancies is a major market driver.

    Market Size & Forecast

    2024 Market Size 300 (USD Million)
    2035 Market Size 2035 (USD Million)
    CAGR (2025-2035) 15.76%

    Major Players

    Merck and Co, Sorrento Therapeutics, Celgene, Novartis, Zymeworks, Adeptus Health, Bristol-Myers Squibb, Gilead Sciences, bluebird bio, Pfizer, Amgen, CARTISTEM, Altor BioScience, Celltrion, Celyad Oncology

    GCC Car T Cell Therapy Market Trends

    The market for GCC CAR T cell therapy is expanding significantly due to a number of important considerations. The rising incidence of hematological malignancies in the area, which has increased demand for cutting-edge treatment alternatives, is one of the main factors propelling the market.

    In keeping with Vision 2030 plans to improve patient care and provide access to cutting-edge cures, governments in the GCC are also making investments in healthcare research and infrastructure.

    Furthermore, collaborations between international pharmaceutical firms and regional healthcare providers are growing more frequent, which promotes information sharing and the launch of innovative CAR T cell treatments.

    Recent developments in the GCC point to a move toward personalized medicine, with a greater focus on customizing treatments for each patient's unique profile. Improvements in data analytics and genomic research are the foundation of this trend, allowing medical practitioners to provide more efficient treatment regimens.

    A more hospitable environment for the commercialization of CAR T cell therapies is also being created by the way regulatory frameworks in nations like Saudi Arabia and the United Arab Emirates are changing to facilitate quicker approvals and accommodate new treatments. There are several opportunities in the industry, especially in the areas of CAR T cell therapy research projects and clinical trials.

    Collaborations between pharmaceutical companies, healthcare providers, and academic institutions can improve these chances. The GCC is poised to become a regional center for CAR T cell therapy, further strengthening its position as a major participant in the global healthcare scene, with further efforts to set up specialized treatment facilities and training programs for medical professionals.

    Market Segment Insights

    CAR T Cell Therapy Market Therapeutic Area Insights

    The GCC CAR T Cell Therapy Market within the Therapeutic Area segment is witnessing considerable growth, showcasing a diverse potential across multiple healthcare domains.

    The region is experiencing a significant shift toward advanced therapeutic solutions, particularly in Oncology, where CAR T cell therapies are revolutionizing the treatment paradigm for various hematologic malignancies and solid tumors.

    The drive toward investment in these therapies can be attributed to the escalating incidence of cancer, bolstered by increasing awareness and advanced healthcare infrastructure throughout the GCC region.

    In addition to Oncology, the realm of Autoimmune Diseases is becoming a focal point for innovation, with CAR T cell therapies aiming to harness the body's immune response to combat disorders that have proven challenging to treat with conventional methods.

    This is particularly important given the rise of autoimmune disorders in the GCC, attributed to lifestyle changes and environmental factors, thereby driving the search for effective immunotherapeutic alternatives.

    CAR T Cell Therapy Market Cell Source Insights

    The GCC CAR T Cell Therapy Market, particularly within the Cell Source segment, is poised for substantial advancements driven by increasing healthcare investments and technological innovations in the region. Autologous CAR T cell therapies have gained traction due to their personalized approach, offering patients tailored treatment options that utilize their own T cells.

    This method significantly enhances the chances of effective treatment outcomes by minimizing the risk of rejection. Conversely, Allogeneic therapies are emerging as a pivotal area, providing the prospect of off-the-shelf formulations that can cater to a broader patient base, ultimately enhancing accessibility to CAR T therapies.

    Additionally, Gene-Edited technologies are reshaping the landscape by enabling enhancements in the efficacy and safety profiles of products, addressing challenges such as resistance and relapse.

    As governments in the GCC are focusing on healthcare transformation initiatives, collaboration between public and private sectors has risen, presenting diverse opportunities for stakeholders in the CAR T Cell Therapy Market.

    The collective growth in these subcategories is not only anticipated to drive market dynamics but also to pivot the GCC region towards becoming a hub for innovative cancer treatments as they align with global healthcare trends.

    CAR T Cell Therapy Market Indication Insights

    The GCC CAR T Cell Therapy Market is becoming increasingly significant, particularly within the Indication segment, which encompasses various hematological malignancies. Acute Lymphoblastic Leukemia (ALL) has emerged as a prominent focus area due to its high prevalence among pediatric patients, leading to increased demand for targeted therapies.

    Non-Hodgkin Lymphoma (NHL) also represents a critical category characterized by diverse subtypes that warrant customized treatment approaches, contributing to the evolution of CAR T cell therapies. Meanwhile, Multiple Myeloma has been gaining attention given the rising number of diagnoses in the GCC region, highlighting a viable market for innovative treatment options.

    The growing investment in healthcare infrastructure and advancements in Research and Development within the GCC further underline the potential for breakthroughs in treating these conditions.

    The rising awareness about novel therapies and their benefits, coupled with supportive government initiatives, especially in countries like Saudi Arabia and the UAE, is expected to drive the market forward in the upcoming years.

    Overall, the Indication segment encapsulates a vital aspect of the GCC CAR T Cell Therapy Market, reflecting the urgent need for effective solutions in combating hematological cancers.

    CAR T Cell Therapy End-user Insights

    The End-user segment of the GCC CAR T Cell Therapy Market plays a crucial role in the overall dynamics of healthcare in the region. Hospitals serve as the primary point of care, equipped with advanced technologies and facilities to administer CAR T cell therapies effectively.

    They handle the majority of patient treatments, ensuring access to cutting-edge therapies amid the increasing prevalence of cancers in the GCC region. Research Institutes are pivotal for innovation, enhancing the understanding of CAR T cell therapies through clinical trials and research.

    They drive advancements in treatment effectiveness and safety protocols. Cancer Treatment Centers complement these efforts by providing specialized care and support throughout patients' treatment journeys, focusing on personalized therapy approaches.

    The GCC region is experiencing growth in healthcare investments, with governments emphasizing the development of world-class healthcare facilities, enhancing the capacity and specialty of hospitals and treatment centers.

    This growth, alongside a focus on Research and Development, allows for emerging collaboration between hospitals, research institutions, and specialized centers, ultimately increasing the accessibility and efficacy of CAR T Cell therapies in the GCC.

    Get more detailed insights about GCC Car T Cell Therapy Market Research Report — Global Forecast till 2035

    Key Players and Competitive Insights

    The GCC CAR T Cell Therapy Market is characterized by rapid advancements in biotechnology and an increasing emphasis on personalized medicine. The competition within this segment has intensified as various companies strive to secure their foothold through innovative therapies and strategic alliances.

    The market is shaped by the need for cutting-edge treatments for hematological malignancies and solid tumors, leading to a race among key players to develop novel CAR T therapies that are not only effective but also can be produced at a viable scale.

    With the regulatory landscape evolving, companies are also focusing on navigating complex approval processes while establishing partnerships with healthcare providers to enhance their market presence and drive adoption among oncologists and hematologists.

    Merck and Co

    Merck and Co. command a significant position in the GCC CAR T Cell Therapy Market, leveraging its global experience and robust research capabilities to enhance its offerings in the region. The company's strengths lie in its comprehensive pipeline of innovative therapies, extensive R&D investments, and established relationships with local healthcare providers.

    Merck's commitment to advancing CAR T Cell Therapy has propelled its visibility among oncology departments within GCC countries, fostering collaborations that amplify its market outreach. Their strategic initiatives include ongoing clinical trials focused on optimizing existing therapies and developing new solutions tailored to the specific needs of patients in the GCC region.

    This, in turn, fortifies Merck's reputation as a leader in cancer treatment and reinforces its role in shaping the CAR T Cell landscape.

    Sorrento Therapeutics

    Sorrento Therapeutics is gaining recognition in the GCC CAR T Cell Therapy Market, particularly through its innovative approaches to cellular therapy. The company focuses on developing next-generation CAR T products aimed at treating various malignancies, thus expanding its operational scope in the region. Sorrento has established a market presence through key strategic partnerships and collaborations that enable it to commercialize its therapies effectively while adhering to regulatory requirements.

    The company boasts a strong portfolio of proprietary products, including both first and second-generation CAR T therapies, alongside their advancements in dual-targeted therapies, which broaden treatment options for patients.

    Furthermore, Sorrento's proactive mergers and acquisitions strategy has helped it acquire essential technologies and enhance its competitive positioning in the region, allowing it to streamline operations and accelerate innovation in CAR T Cell therapies specifically designed for the GCC market.

    Key Companies in the GCC Car T Cell Therapy Market market include

    Industry Developments

    The GCC CAR T Cell Therapy Market has witnessed significant advancements recently. In October 2023, Gilead Sciences announced the successful initiation of its CAR T cell therapy clinical trials in the UAE, aiming to treat specific blood cancers.

    Meanwhile, Novartis has strengthened its foothold in the region by partnering with local healthcare providers to increase access to its CAR T therapy, Kymriah, significantly impacting patient treatment options. Zymeworks also opened a new facility in Saudi Arabia, focusing on Research and Development for personalized immunotherapies.

    In terms of mergers and acquisitions, Bristol-Myers Squibb acquired a stake in a regional biopharmaceutical firm in April 2023 to enhance its CAR T pipeline. Market valuations have shown promising growth, with projections from the UAE Ministry of Health indicating a rise in investments in innovative therapies.

    Furthermore, the establishment of dedicated cancer treatment centers across the region continues to drive demand and foster collaboration among pharmaceutical companies like Merck and Co, Sorrento Therapeutics, and Bluebird Bio, ensuring that advancements in CAR T cell therapy are effectively translated into clinical practice for GCC patients.

    Market Segmentation

    CAR T Cell Therapy Market End-user Outlook

    • Hospitals
    • Research Institutes
    • Cancer Treatment Centers

    CAR T Cell Therapy Market Indication Outlook

    • Acute Lymphoblastic Leukemia
    • Non-Hodgkin Lymphoma
    • Multiple Myeloma

    CAR T Cell Therapy Market Cell Source Outlook

    • Autologous
    • Allogeneic
    • Gene-Edited

    CAR T Cell Therapy Market Therapeutic Area Outlook

    • Oncology
    • Autoimmune Diseases
    • Infectious Diseases

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 240.0(USD Million)
    MARKET SIZE 2024 300.0(USD Million)
    MARKET SIZE 2035 1500.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 15.756% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2023
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Merck and Co, Sorrento Therapeutics, Celgene, Novartis, Zymeworks, Adeptus Health, BristolMyers Squibb, Gilead Sciences, bluebird bio, Pfizer, Amgen, CARTISTEM, Altor BioScience, Celltrion, Celyad Oncology
    SEGMENTS COVERED Therapeutic Area, Cell Source, Indication, End User
    KEY MARKET OPPORTUNITIES Growing cancer incidence rates, Increased healthcare investments, Collaboration with local biotech firms, Expanding clinical trial landscape, Rising demand for personalized medicine
    KEY MARKET DYNAMICS Rising cancer prevalence, Increased healthcare investments, Growing adoption of advanced therapies, Expanding clinical trial activities, Regulatory support for innovations
    COUNTRIES COVERED GCC

    FAQs

    What is the expected market size of the GCC CAR T Cell Therapy Market in 2024?

    The GCC CAR T Cell Therapy Market is expected to be valued at 300.0 USD Million in 2024.

    What will be the market size of the GCC CAR T Cell Therapy Market by 2035?

    By 2035, the market size is projected to reach 1500.0 USD Million.

    What is the expected CAGR for the GCC CAR T Cell Therapy Market from 2025 to 2035?

    The expected CAGR for the market during this period is 15.756%.

    Which therapeutic area holds the largest market share in 2024?

    In 2024, the oncology segment is valued at 180.0 USD Million, making it the largest therapeutic area.

    How much is the Autoimmune Diseases segment projected to grow by 2035?

    The Autoimmune Diseases segment is expected to grow to 400.0 USD Million by 2035.

    What are the estimated market values for the Infectious Diseases segment in 2024 and 2035?

    In 2024, the Infectious Diseases segment is valued at 40.0 USD Million and is expected to reach 200.0 USD Million by 2035.

    Who are the key players in the GCC CAR T Cell Therapy Market?

    Major players in the market include Merck & Co, Novartis, Gilead Sciences, and Bristol-Myers Squibb, among others.

    What is the anticipated growth rate for the oncology segment from 2025 to 2035?

    The oncology segment is likely to see significant growth, contributing to a substantial portion of the overall market increase.

    What opportunities are driving the growth of the GCC CAR T Cell Therapy Market?

    Advancements in technology and increasing prevalence of cancers drive growth in this market.

    What are the emerging trends in the GCC CAR T Cell Therapy Market?

    Key trends include the development of personalized therapies and improved delivery methods, enhancing patient outcomes.

    GCC Car T Cell Therapy Market Research Report — Global Forecast till 2035 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study
    Chemicals and Materials